CRB’s Horizons series of industry reports pools the talents and expertise of our leading subject matter experts to understand the conditions and forces affecting the life sciences and food and beverage industries. Based on hundreds of surveys of industry leaders, our free reports go deep on the critical trends driving the markets and how companies can stay on the leading edge.
HORIZONS
Introducing the newest addition to our series of Horizons reports: Market Conditions. Released quarterly, this provides in-depth data paired with expert analysis on how wider economic events will affect the construction industry.
2023 Q1 Horizons Market Conditions Report
The first installment of our quarterly Horizons: Market Conditions report finds capital project planning vexed by extreme uncertainty that permeates both the supply chain and labor pool, as rising interest rates and the expectation of a recession loom over the economy.
Read More
2023 Alternative Proteins
This report explores the factors affecting the efficient and profitable scale-up of the alternative proteins market, covering everything from processing and operations to sustainability and regulations.
Read More
2022 Life Sciences Report
This report explores an industry that is investing in novel research, pushing against long-established comfort zones, and moving cautiously but steadily toward an advanced standard of care for critically ill patients.
Read More
2022 Pet Food Report
As consumers increasingly seek out high-quality, ethically-sourced, and sustainably-made pet food and treats, manufacturers must navigate new challenges and opportunities.
Read More
2021 Life Sciences Report
We explore the disruptive forces reshaping how biopharma companies speed life-saving therapies and vaccines to the market.
Read More
2021 Alternative Proteins Report
Growing demand for alternative proteins has manufacturers reconsidering everything from packaging and safety to regulation and project delivery.
Read More
2020 Cell & Gene Therapy Report
Through a survey of nearly 150 industry leaders, our inaugural CRB Horizons: Cell and Gene Therapy report finds the biopharma space at a critical inflection point.
Read More
